サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：出血性疾患治療薬の世界市場 (～2027年)：薬剤タイプ・疾患タイプ・流通チャネル・エンドユーザー・地域別の競合・機会・予測
市場調査レポート
商品コード
1121071

出血性疾患治療薬の世界市場 (～2027年)：薬剤タイプ・疾患タイプ・流通チャネル・エンドユーザー・地域別の競合・機会・予測

Global Bleeding Disorders Treatment Market By Drug Type, By Disease Type, By Distribution Channel, By End User By Region, Competition, Forecast & Opportunities, 2027
出版日: | 発行: TechSci Research | ページ情報: 英文 114 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

出血性疾患治療薬の世界市場 (～2027年)：薬剤タイプ・疾患タイプ・流通チャネル・エンドユーザー・地域別の競合・機会・予測
出版日: 2022年09月01日
発行: TechSci Research
ページ情報: 英文 114 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の出血性疾患治療薬の市場は、予測期間である2023年から2027年にかけて安定したCAGRを記録すると予測されています。

患者人口の増加、官民の事業者による医療支出の増加、中流世帯の可処分所得の増加などの要因が同市場を牽引しています。また、R&D活動の進行や、製薬会社が遺伝子組み換え製品に注力するようになったことで、今後5年間は市場に有利な成長機会が生まれると予想されています。

当レポートでは、世界の出血性疾患治療薬の市場を調査し、市場概要、市場規模の推移・予測、各種区分・地域/主要国別の内訳、市場への各種影響因子の分析、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19：世界の出血性疾患治療薬市場に与える影響

第5章 VOC (顧客の声)

第6章 世界の出血性疾患治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 薬剤タイプ別（血漿由来凝固因子濃縮物・組換え凝固因子濃縮物・デスモプレシン・抗線溶薬・フィブリンシーラント・その他）
    • 疾患タイプ別（血友病A・血友病B・フォンヴィレブランド病・その他）
    • 流通チャネル別（病院薬局・小売薬局・オンライン）
    • エンドユーザー別（クリニック・病院・研究機関・その他）
    • 企業別
    • 地域別（北米・欧州・アジア太平洋・南米・中東&アフリカ）
  • 製品市場マップ

第7章 北米の出血性疾患治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 薬剤タイプ別
    • 疾患タイプ別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第8章 欧州の出血性疾患治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 薬剤タイプ別
    • 疾患タイプ別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第9章 アジア太平洋の出血性疾患治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 薬剤タイプ別
    • 疾患タイプ別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第10章 中東およびアフリカの出血性疾患治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 薬剤タイプ別
    • 疾患タイプ別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第11章 南米の出血性疾患治療薬市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 薬剤タイプ別
    • 疾患タイプ別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向・市場展開

第14章 競合情勢

  • 競合の見通し
  • 世界の企業プロファイル
    • Bayer AG
    • Pfizer Inc.
    • Grifols S.A.
    • Octapharma AG
    • Sun Pharmaceuticals Industries Ltd.
    • Ferring Pharmaceuticals SA
    • Amgen Inc.
    • Sanofi SA
    • Baxter International Inc.
    • F. Hoffmann-La Roche Ltd.
    • Takeda Pharmaceuticals Ltd.
    • Novo Nordisk A/S
    • Novartis AG
    • Eli Lilly and Company Ltd.
    • Gilead Sciences Inc.

第15章 戦略的提言

第16章 当社について&免責事項

目次
Product Code: 7317

The global bleeding disorders treatment market is projected to witness a steady CAGR during the forecast period, 2023-2027. Factors such as the rise in the patient population base, increased healthcare expenditure by the public and private players, and growing disposable income for middle-class families drive the global bleeding disorders treatment market. The ongoing research and development activities and the increased focus of pharmaceutical companies on recombinant products are expected to create lucrative growth opportunities for the global bleeding disorders treatment market in the next five years. However, limited reimbursement and the high cost of availing of bleeding disorder treatment facilities may hinder the market growth in the forecast period.

The global bleeding disorders treatment market is segmented into drug type, disease type, distribution channel, end user, regional distribution, and competitive landscape. Based on drug type, the market is fragmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants, and others. The recombinant coagulation factor concentrates segment is expected to capture the highest market share during the forecast period, 2023-2027. Their high efficiency in preventing bleeding than plasma-derived coagulation factor concentrates is expected to drive the market demand in the next five years.

North America is expected to dominate the global bleeding disorders treatment market in the forecast period. The compatibility of the population of all age groups in the United States for prophylaxis treatment is driving the market demand in the region.

The major players operating in the global bleeding disorders treatment market are: Bayer AG, Pfizer Inc., Grifols S.A., Octapharma AG, Sun Pharmaceuticals Industries Ltd., Ferring Pharmaceuticals SA, Amgen Inc., Sanofi SA, Baxter International Inc., F. Hoffmann-La Roche Ltd., Takeda Pharmaceuticals Ltd., Novo Nordisk A/S, Novartis AG, Eli Lilly and Company Ltd., Gilead Sciences Inc., among others. The companies are focusing on extensive research and development activities to stay competitive in the market.

Years considered for this report:

  • Historical Years: 2017 - 2020
  • Base Year: 2021
  • Estimated Year: 2022
  • Forecast Period: 2023 - 2027

Objective of the Study:

  • To analyze and forecast the market size of global bleeding disorders treatment market from 2017 to 2021.
  • To estimate and forecast the market size of global bleeding disorders treatment market from 2022 to 2027 and growth rate until 2027.
  • To classify and forecast global bleeding disorders treatment market based on drug type, disease type, distribution channel, end user, and regional distribution.
  • To identify dominant region or segment in the global bleeding disorders treatment market.
  • To identify drivers and challenges for global bleeding disorders treatment market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in Global bleeding disorders treatment market.
  • To identify and analyze the profile of leading players operating in Global bleeding disorders treatment market.
  • To identify key sustainable strategies adopted by market players in Global bleeding disorders treatment market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of Global bleeding disorders treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Bleeding disorders treatment vendors, end users, service providers and other stakeholders
  • Distributers and suppliers of bleeding disorders treatment's products and services and other stakeholders
  • Organizations, forums, and alliances related to bleeding disorders treatment
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, Global bleeding disorders treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Market, By Drug Type:

  • Plasma-derived Coagulation Factor Concentrates
  • Recombinant Coagulation Factor Concentrates
  • Desmopressin
  • Antifibrinolytics
  • Fibrin Sealants
  • Others

Market, By Disease Type:

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Others

Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online

Market, By End User:

  • Clinics
  • Hospitals
  • Research Institutes
  • Others

Market, By Region:

  • North America
  • APAC
  • Europe
  • MEA
  • South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global bleeding disorders treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Bleeding Disorders Treatment Market

4. Executive Summary

5. Voice of Customer

6. Global Bleeding Disorders Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Others)
    • 6.2.2. By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others)
    • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online)
    • 6.2.4. By End User (Clinics, Hospitals, Research Institutes, Others)
    • 6.2.5. By Company (2021)
    • 6.2.6. By Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa)
  • 6.3. Product Market Map

7. North America Bleeding Disorders Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Disease Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By End User
    • 7.2.5. By Country (United States; Canada; Mexico)
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Bleeding Disorders Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Disease Type
        • 7.3.1.2.3. By Distribution Channel
        • 7.3.1.2.4. By End User
    • 7.3.2. Canada Bleeding Disorders Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Disease Type
        • 7.3.2.2.3. By Distribution Channel
        • 7.3.2.2.4. By End User
    • 7.3.3. Mexico Bleeding Disorders Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Disease Type
        • 7.3.3.2.3. By Distribution Channel
        • 7.3.3.2.4. By End User

8. Europe Bleeding Disorders Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Disease Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By End User
    • 8.2.5. By Country (France; Germany; UK; Italy; Spain)
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Bleeding Disorders Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Disease Type
        • 8.3.1.2.3. By Distribution Channel
        • 8.3.1.2.4. By End User
    • 8.3.2. Germany Bleeding Disorders Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Disease Type
        • 8.3.2.2.3. By Distribution Channel
        • 8.3.2.2.4. By End User
    • 8.3.3. United Kingdom Bleeding Disorders Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Disease Type
        • 8.3.3.2.3. By Distribution Channel
        • 8.3.3.2.4. By End User
    • 8.3.4. Italy Bleeding Disorders Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Disease Type
        • 8.3.4.2.3. By Distribution Channel
        • 8.3.4.2.4. By End User
    • 8.3.5. Spain Bleeding Disorders Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Disease Type
        • 8.3.5.2.3. By Distribution Channel
        • 8.3.5.2.4. By End User

9. Asia-Pacific Bleeding Disorders Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Disease Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By End User
    • 9.2.5. By Country (China; India; Japan; South Korea; Australia)
  • 8.3 Asia-Pacific: Country Analysis
    • 8.3.1 China Bleeding Disorders Treatment Market Outlook
      • 8.3.1.1 Market Size & Forecast
        • 8.3.1.1.1 By Value
      • 8.3.1.2 Market Share & Forecast
        • 8.3.1.2.1 By Drug Type
        • 8.3.1.2.2 By Disease Type
        • 8.3.1.2.3 By Distribution Channel
        • 8.3.1.2.4 By End User
    • 8.3.2 India Bleeding Disorders Treatment Market Outlook
      • 8.3.2.1 Market Size & Forecast
        • 8.3.2.1.1 By Value
      • 8.3.2.2 Market Share & Forecast
        • 8.3.2.2.1 By Drug Type
        • 8.3.2.2.2 By Disease Type
        • 8.3.2.2.3 By Distribution Channel
        • 8.3.2.2.4 By End User
    • 8.3.3 Japan Bleeding Disorders Treatment Market Outlook
      • 8.3.3.1 Market Size & Forecast
        • 8.3.3.1.1 By Value
      • 8.3.3.2 Market Share & Forecast
        • 8.3.3.2.1 By Drug Type
        • 8.3.3.2.2 By Disease Type
        • 8.3.3.2.3 By Distribution Channel
        • 8.3.3.2.4 By End User
    • 8.3.4 South Korea Bleeding Disorders Treatment Market Outlook
      • 8.3.4.1 Market Size & Forecast
        • 8.3.4.1.1 By Value
      • 8.3.4.2 Market Share & Forecast
        • 8.3.4.2.1 By Drug Type
        • 8.3.4.2.2 By Disease Type
        • 8.3.4.2.3 By Distribution Channel
        • 8.3.4.2.4 By End User
    • 8.3.5 Australia Bleeding Disorders Treatment Market Outlook
      • 8.3.5.1 Market Size & Forecast
        • 8.3.5.1.1 By Value
      • 8.3.5.2 Market Share & Forecast
        • 8.3.5.2.1 By Drug Type
        • 8.3.5.2.2 By Disease Type
        • 8.3.5.2.3 By Distribution Channel
        • 8.3.5.2.4 By End User

10. Middle East and Africa Bleeding Disorders Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Disease Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By End User
    • 10.2.5. By Country (UAE; Saudi Arabia; South Africa)
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bleeding Disorders Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Disease Type
        • 10.3.1.2.3. By Distribution Channel
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Bleeding Disorders Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Disease Type
        • 10.3.2.2.3. By Distribution Channel
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Bleeding Disorders Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Disease Type
        • 10.3.3.2.3. By Distribution Channel
        • 10.3.3.2.4. By End User

11. South America Bleeding Disorders Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Type
    • 11.2.2. By Disease Type
    • 11.2.3. By Distribution Channel
    • 11.2.4. By End User
    • 11.2.5. By Country (Brazil; Argentina; Colombia)
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Bleeding Disorders Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Type
        • 11.3.1.2.2. By Disease Type
        • 11.3.1.2.3. By Distribution Channel
        • 11.3.1.2.4. By End User
    • 11.3.2. Argentina Bleeding Disorders Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Type
        • 11.3.2.2.2. By Disease Type
        • 11.3.2.2.3. By Distribution Channel
        • 11.3.2.2.4. By End User
    • 11.3.3. Colombia Bleeding Disorders Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Type
        • 11.3.3.2.2. By Disease Type
        • 11.3.3.2.3. By Distribution Channel
        • 11.3.3.2.4. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Global Players Profiled (Leading Companies)
    • 14.2.1. Bayer AG
    • 14.2.2. Pfizer Inc.
    • 14.2.3. Grifols S.A.
    • 14.2.4. Octapharma AG
    • 14.2.5. Sun Pharmaceuticals Industries Ltd.
    • 14.2.6. Ferring Pharmaceuticals SA
    • 14.2.7. Amgen Inc.
    • 14.2.8. Sanofi SA
    • 14.2.9. Baxter International Inc.
    • 14.2.10. F. Hoffmann-La Roche Ltd.
    • 14.2.11. Takeda Pharmaceuticals Ltd.
    • 14.2.12. Novo Nordisk A/S
    • 14.2.13. Novartis AG
    • 14.2.14. Eli Lilly and Company Ltd.
    • 14.2.15. Gilead Sciences Inc.

15. Strategic Recommendations

16. About Us & Disclaimer